loading page

Gilteritinib-induced severe immune-related enteritis: a possible case report
  • +5
  • Pan Luo,
  • Huiyin Qiu,
  • Yushan Yang,
  • Jiaqi Wu,
  • Xianmin Song,
  • Guorong Fan,
  • Gaolin Liu,
  • Junwei Gao
Pan Luo

Corresponding Author:[email protected]

Author Profile
Huiyin Qiu
Author Profile
Yushan Yang
Author Profile
Xianmin Song
Author Profile
Guorong Fan
Author Profile
Gaolin Liu
Author Profile
Junwei Gao
Shanghai Jiaotong University First People's Hospital
Author Profile


This case report describes a 49-year-old woman who diagnosed with acute myeloid leukaemia (AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations developed a severe suspected immune-related enteritis during treatment with gilteritinib for maintenance therapy following allo-hematopoietic stem cell transplantation (HSCT). According to the results of Naranjo probability scale, gilteritinib was defined as a ‘possible’ cause of the adverse drug reaction (ADR). Another suspicious inducement, graft-versus-host disease (GVHD), can not be eluted might represent a limitation in this case. To the best of our knowledge, this is the first report on gilteritinib-induced severe enteritis, and will help physicians to keep vigilant, and detect and deal with timely for the possible ADR.